1. The adeno-associated virus 5 (AAV5)-based gene therapy, valoctocogene roxaparvovec (AAV5-hFVIII-SQ), resulted in sustained factor VIII production, reduced bleeding rates, ...
1. The vaccination resulted in adverse events that were grade 2 or lower with no serious adverse events. 2. Serum ...
1. Efficacy of the Gam-COVID-Vac (Sputnik V) vaccine against COVID-19 was 91.6%. 2. In the vaccine group, there were no ...
1. In this phase 1-2 clinical trial, an adenovirus viral vector expressing non-structural hepatitis C proteins was safe in a ...
Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists The Johnson & Johnson (J&J) Pharmaceutical Research and ...
